Avant Technologies' Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference
Avant Technologies (OTCQB: AVAI) announced that Vinicio Vargas, CEO of their joint venture partner Ainnova Tech, presented at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Colombia. The conference focused on scientific advances in treating common eye diseases and fostering regional collaboration.
Notably, Ainnova formed a strategic alliance with Roche and Salud 360 in Q4 2024 to launch a pilot program using their AI-powered Vision AI technology to combat diabetic retinopathy. If successful, the program could expand to the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights for Ainnova's technology portfolio.
Avant Technologies (OTCQB: AVAI) ha annunciato che Vinicio Vargas, CEO del loro partner in joint venture Ainnova Tech, ha presentato alla conferenza oftalmologica "Macular Spectacular" di Roche per l'America Latina, tenutasi in Colombia. La conferenza si è concentrata sui progressi scientifici nel trattamento delle comuni malattie oculari e sulla promozione della collaborazione regionale.
In particolare, Ainnova ha stretto una alleanza strategica con Roche e Salud 360 nel quarto trimestre del 2024 per avviare un programma pilota che utilizza la loro tecnologia Vision AI basata sull'intelligenza artificiale per combattere la retinopatia diabetica. Se il programma avrà successo, potrebbe estendersi agli Stati Uniti, Canada ed Europa tramite Ai-nova Acquisition Corp. (AAC), che detiene i diritti di licenza mondiali sul portafoglio tecnologico di Ainnova.
Avant Technologies (OTCQB: AVAI) anunció que Vinicio Vargas, CEO de su socio en la empresa conjunta Ainnova Tech, presentó en la conferencia oftalmológica "Macular Spectacular" de Roche para América Latina, celebrada en Colombia. La conferencia se centró en los avances científicos en el tratamiento de enfermedades oculares comunes y en fomentar la colaboración regional.
En particular, Ainnova formó una alianza estratégica con Roche y Salud 360 en el cuarto trimestre de 2024 para lanzar un programa piloto que utiliza su tecnología Vision AI impulsada por inteligencia artificial para combatir la retinopatía diabética. Si el programa tiene éxito, podría expandirse a Estados Unidos, Canadá y Europa a través de Ai-nova Acquisition Corp. (AAC), que posee los derechos de licencia mundial para el portafolio tecnológico de Ainnova.
Avant Technologies (OTCQB: AVAI)는 합작 파트너인 Ainnova Tech의 CEO Vinicio Vargas가 콜롬비아에서 열린 Roche 라틴 아메리카 "Macular Spectacular" 안과 컨퍼런스에서 발표했다고 발표했습니다. 이 컨퍼런스는 일반적인 안구 질환 치료에 대한 과학적 진보와 지역 협력 증진에 중점을 두었습니다.
특히, Ainnova는 2024년 4분기에 Roche 및 Salud 360과 전략적 제휴를 맺고 인공지능 기반 Vision AI 기술을 활용해 당뇨병성 망막병증을 치료하는 파일럿 프로그램을 시작했습니다. 이 프로그램이 성공하면, Ainnova의 기술 포트폴리오에 대한 전 세계 라이선스 권리를 보유한 Ai-nova Acquisition Corp. (AAC)을 통해 미국, 캐나다, 유럽으로 확장될 수 있습니다.
Avant Technologies (OTCQB : AVAI) a annoncé que Vinicio Vargas, PDG de leur partenaire en coentreprise Ainnova Tech, a présenté lors de la conférence ophtalmologique "Macular Spectacular" de Roche pour l'Amérique latine, qui s'est tenue en Colombie. La conférence s'est concentrée sur les avancées scientifiques dans le traitement des maladies oculaires courantes et sur la promotion de la collaboration régionale.
Notamment, Ainnova a formé une alliance stratégique avec Roche et Salud 360 au 4e trimestre 2024 pour lancer un programme pilote utilisant leur technologie Vision AI alimentée par l'intelligence artificielle afin de lutter contre la rétinopathie diabétique. En cas de succès, le programme pourrait s'étendre aux États-Unis, au Canada et en Europe via Ai-nova Acquisition Corp. (AAC), qui détient les droits de licence mondiaux sur le portefeuille technologique d'Ainnova.
Avant Technologies (OTCQB: AVAI) gab bekannt, dass Vinicio Vargas, CEO ihres Joint-Venture-Partners Ainnova Tech, auf der Ophthalmologie-Konferenz "Macular Spectacular" von Roche für Lateinamerika in Kolumbien präsentierte. Die Konferenz konzentrierte sich auf wissenschaftliche Fortschritte bei der Behandlung häufiger Augenerkrankungen und die Förderung regionaler Zusammenarbeit.
Bemerkenswert ist, dass Ainnova im 4. Quartal 2024 eine strategische Allianz mit Roche und Salud 360 einging, um ein Pilotprogramm mit ihrer KI-basierten Vision AI-Technologie zur Bekämpfung der diabetischen Retinopathie zu starten. Bei Erfolg könnte das Programm über Ai-nova Acquisition Corp. (AAC), die weltweit die Lizenzrechte für Ainnovas Technologieportfolio hält, auf die USA, Kanada und Europa ausgeweitet werden.
- Strategic alliance with major players Roche and Salud 360 for Vision AI pilot program
- Potential expansion opportunities into US, Canada, and Europe markets
- Worldwide licensing rights secured for Ainnova's technology portfolio through AAC
- Success of pilot program not yet proven
- Limited current geographical presence (only Latin America)
The conference highlighted the latest in scientific advances in treatments for the most common eye diseases, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, while also focusing on strengthening collaboration between industry specialists in
Ainnova's CEO, Vinicio Vargas, who is also a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, discussed the status of AI and its uses in the industry to improve patient outcomes. Vargas and a host of renowned speakers that included Dr. Laura Velásquez, Dr. Roberto Gallego, Hugo Ocampo, and other ophthalmologists and experts presented the latest tools to transform visual health in the region, reflected on unmet needs, and explained how innovation can help build stronger, accessible, and patient-centered health systems.
In Q4 2024, Ainnova entered a strategic alliance with global biotech, Roche, and leading prepaid health plan provider, Salud 360, to start a pilot program to combat diabetic retinopathy using Ainnova's AI-powered, cutting-edge technology, Vision AI. The alliance aims at improving access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy.
If the program is successful, Avant and Ainnova hope to implement a similar program in
About Ainnova Tech, Inc.
Ainnova is a
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
info@avanttechnologies.com
Logo - https://mma.prnewswire.com/media/2370694/5425228/Avant_Technologies.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-joint-venture-partner-presents-ai-technology-at-roche-ophthalmology-conference-302510577.html
SOURCE Avant Technologies Inc.
FAQ
What is the strategic alliance between Avant Technologies (AVAI) and Roche?
What is Avant Technologies' Vision AI technology used for?
Who are the key partners in Avant Technologies' (AVAI) AI healthcare venture?
What are Avant Technologies' (AVAI) expansion plans for Vision AI?
What markets does Avant Technologies' Vision AI currently operate in?
